EA202191361A1 - Способы лечения муковисцидоза - Google Patents

Способы лечения муковисцидоза

Info

Publication number
EA202191361A1
EA202191361A1 EA202191361A EA202191361A EA202191361A1 EA 202191361 A1 EA202191361 A1 EA 202191361A1 EA 202191361 A EA202191361 A EA 202191361A EA 202191361 A EA202191361 A EA 202191361A EA 202191361 A1 EA202191361 A1 EA 202191361A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
mucoviscidosis
treatment
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
EA202191361A
Other languages
English (en)
Inventor
Дэвид М. Альтшулер
Кори Дон Андерсон
Вэйчао Джордж Чэнь
Джереми Дж. Клеменс
Томас Кливленд
Тимоти Ричард Кун
Брайан Фримен
Сара Сабина Адида Руа
Брайн Дж. Хеа
Решма Кевалрамани
Джейсон Маккартни
Марк Томас Миллер
Прасуна Параселли
Фабрис Пьер
Сара М. Робертсон
Патрик Р. Сосней
Сара И. Свифт
Цзинлань ЧЖОУ
Бартломей Борек
Фредрик Ван Гор
Тим Юн
Original Assignee
Вертекс Фармасьютикалз Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68808572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202191361(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вертекс Фармасьютикалз Инкорпорейтед filed Critical Вертекс Фармасьютикалз Инкорпорейтед
Publication of EA202191361A1 publication Critical patent/EA202191361A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описаны способы лечения муковисцидоза или заболевания, опосредованного CFTR, включающие введение соединения I или его фармацевтически приемлемой соли. В данной заявке также описаны фармацевтические композиции, содержащие соединение I или его фармацевтически приемлемую соль и необязательно содержащие одно или более дополнительных средств, модулирующих CFTR.
EA202191361A 2018-11-14 2019-11-13 Способы лечения муковисцидоза EA202191361A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862767202P 2018-11-14 2018-11-14
PCT/US2019/061171 WO2020102346A1 (en) 2018-11-14 2019-11-13 Methods of treatment for cystic fibrosis

Publications (1)

Publication Number Publication Date
EA202191361A1 true EA202191361A1 (ru) 2021-08-11

Family

ID=68808572

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191361A EA202191361A1 (ru) 2018-11-14 2019-11-13 Способы лечения муковисцидоза

Country Status (22)

Country Link
US (1) US20220047564A1 (ru)
EP (2) EP4218754A3 (ru)
AU (1) AU2019381750A1 (ru)
BR (1) BR112021009145A2 (ru)
CA (1) CA3123578A1 (ru)
CL (1) CL2021001248A1 (ru)
CO (1) CO2021007447A2 (ru)
DK (1) DK3880197T3 (ru)
EA (1) EA202191361A1 (ru)
ES (1) ES2943126T3 (ru)
FI (1) FI3880197T3 (ru)
HR (1) HRP20230272T1 (ru)
HU (1) HUE061686T2 (ru)
IL (1) IL282988A (ru)
LT (1) LT3880197T (ru)
MA (1) MA54227B1 (ru)
MD (1) MD3880197T2 (ru)
PL (1) PL3880197T3 (ru)
PT (1) PT3880197T (ru)
RS (1) RS64192B1 (ru)
SI (1) SI3880197T1 (ru)
WO (1) WO2020102346A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020010335A2 (pt) * 2017-12-01 2020-11-10 Vertex Pharmaceuticals Incorporated processos para produzir moduladores de regulador de condutância de transmembrana de fibrose cística
SG11202006614VA (en) 2018-02-15 2020-08-28 Vertex Pharma Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
JP2022544383A (ja) * 2019-08-14 2022-10-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒモジュレータの結晶形態
IL303519A (en) 2020-12-10 2023-08-01 Vertex Pharma Cystic fibrosis treatment methods
WO2023150237A1 (en) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2023150236A1 (en) 2022-02-03 2023-08-10 Vertex Pharmaceuticals Incorporated Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol
WO2023154291A1 (en) 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2023224931A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2023224924A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Solid forms of a macrocyclic compounds as cftr modulators and their preparation

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
HUP0501067A2 (en) 2001-11-14 2006-02-28 Teva Pharma Amorphous and crystalline forms of losartan potassium and process for their preparation
ATE534383T1 (de) 2006-05-12 2011-12-15 Vertex Pharma Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid
EP3842037A1 (en) 2008-08-13 2021-06-30 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
AR073709A1 (es) 2008-09-29 2010-11-24 Vertex Pharma Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico
AU2011230508B2 (en) 2010-03-25 2016-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihyderoxypropyl)-6-fluoro-2- (1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide
HUE056525T2 (hu) 2010-04-07 2022-02-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása
NZ603042A (en) 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
MX353408B (es) 2010-04-22 2018-01-11 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
EP2608775A2 (en) 2010-08-27 2013-07-03 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
IL265430B1 (en) 2012-02-27 2024-04-01 Vertex Pharma Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
EP2914248B2 (en) 2012-11-02 2023-10-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cftr mediated diseases
WO2015160787A1 (en) 2014-04-15 2015-10-22 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
CN112279808B (zh) 2014-10-06 2024-03-08 弗特克斯药品有限公司 囊性纤维化跨膜转导调节因子调节剂
US20180353500A1 (en) 2015-09-21 2018-12-13 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
PE20191147A1 (es) 2016-09-30 2019-09-02 Vertex Pharma Modulador de regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador
AU2017352206B2 (en) 2016-10-27 2022-03-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated CFTR potentiators
EP3654969A1 (en) * 2017-07-17 2020-05-27 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019018353A1 (en) * 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
TWI810243B (zh) * 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
SG11202006614VA (en) 2018-02-15 2020-08-28 Vertex Pharma Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them

Also Published As

Publication number Publication date
CO2021007447A2 (es) 2021-12-10
HRP20230272T1 (hr) 2023-04-28
US20220047564A1 (en) 2022-02-17
MA54227B1 (fr) 2023-03-31
DK3880197T3 (da) 2023-03-27
MA54227A (fr) 2021-09-22
BR112021009145A2 (pt) 2021-08-10
WO2020102346A1 (en) 2020-05-22
SI3880197T1 (sl) 2023-04-28
MD3880197T2 (ro) 2023-08-31
LT3880197T (lt) 2023-05-10
AU2019381750A1 (en) 2021-06-24
PT3880197T (pt) 2023-05-09
EP3880197B1 (en) 2023-02-22
EP3880197A1 (en) 2021-09-22
CA3123578A1 (en) 2020-05-20
PL3880197T3 (pl) 2023-07-31
HUE061686T2 (hu) 2023-08-28
IL282988A (en) 2021-06-30
EP4218754A2 (en) 2023-08-02
RS64192B1 (sr) 2023-06-30
EP4218754A3 (en) 2023-08-16
ES2943126T3 (es) 2023-06-09
FI3880197T3 (fi) 2023-05-04
CL2021001248A1 (es) 2021-11-26

Similar Documents

Publication Publication Date Title
EA202191361A1 (ru) Способы лечения муковисцидоза
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CY1123260T1 (el) Ενα αλας νατριου του ν-((1,2,3,5,6,7-eξaϋδpo-s-inδaken-4-υλ)καρβαμοϋλ)-1-ισοπροπυλ-1η-πυραζολο-3-σουλφοναμιδιου
MX2019013954A (es) Inhibidores covalentes de kras.
EA202092490A1 (ru) Модуляторы метилмодифицирующих ферментов, композиции и их применения
BR112019024525A2 (pt) composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c
AU2018351533A8 (en) Crystalline forms and compositions of CFTR modulators
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
EA201992299A1 (ru) Соединения на основе ингибиторов ask1 и их применение
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
CL2022001245A1 (es) Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
CY1121345T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
MX2019001850A (es) Formulaciones para administracion oral de principios activos.
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
EA201692298A1 (ru) Производные карбоксамидов
EA202092540A1 (ru) Комбинации для лечения рака
WO2020128816A3 (en) Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
PH12020551772A1 (en) Oxo-substituted compound